Heregulin (HRG) is an activator of the erbB2-, erbB3-and erbB4-(erbB-2/3/4) signaling pathway. Transfection of full-length HRG cDNA into the estrogen (E2)-dependent cell line MCF-7 promoted an invasive E2-independent phenotype, as well as persistent activation of the erbB-2/3/4 receptors. Moreover, HRG expression in MCF-7 cells renders the cells sensitive to the topoisomerase II inhibitor doxorubicin (Doxo). In an attempt to dissociate the tumorigenic effect of HRG from the sensitizing effect to chemotherapy, we constructed a structural deletion mutant of HRG. Transfection of the deletion mutant of HRG described in this study (HRG/M) into MCF-7 cells resulted in the dissociation of the tumorpromoting activity of HRG from the sensitization to Doxo, that is, although the cells did not become more aggressive or E2-independent they became more sensitive to Doxo. HRG/M was unable to autophosphorylate the erbB receptors and did not affect the level of MAPK phosphorylation. Furthermore, the intracellular localization of the protein was different from that of the fulllength protein. Our data show that the HRG/M sequences are sufficient to sensitize MCF-7 cells to Doxo, and provide evidence that this sensitization is independent of erbB2 activation.
Introduction
Breast cancer progression is regulated in part by growth factors that can mediate a number of biological effects, depending on the cellular context. During the progression process many of the tumors, initially estrogen (E2)-responsive and sensitive to antiestrogenic compounds, become E2-independent and nonresponsive to antiestrogenic therapy. One growth factor that is playing an important role in breast cancer progression is heregulin (HRG).
HRG and its homologous gp30 or Neu differentiation factor are growth factors that are able to activate erbB2 indirectly, through their binding to erbB3 and/or erbB4 (Peles and Yarden, 1993; Tang et al., 1996; Alper et al., 2000) . The activation of the erbB2 receptor, which has been correlated with poor prognosis, can occur via upregulation of expression and dimerization of the receptors, or via formation of heterodimers with erbB3 or erbB4 . HRG is one of the factors that influence the response of the cells to E2. Overexpression of HRG in MCF-7 cells has been shown to confer E2 independence and antiestrogen resistance (Keir et al., 2000) . Furthermore, experimental data in our laboratory have demonstrated that HRG can interfere in the negative crosstalk regulation between erbB2 and the estrogen receptor (ER) (Peles and Yarden, 1993; Alper et al., 2000) . This growth factor is in fact able to antagonize the E2-mediated downregulation of erbB2 expression and is able to enhance the tamoxifen-induced stimulation of erbB2 (Grunt et al., 1995) . The acquired E2-independent phenotype depicts the passage from an initial hormonal responsive and antiestrogen sensitive tumor cell to a later step in carcinogenesis, resembling the inevitable progress of many human breast tumors. The molecular mechanism of this process is not entirely understood.
Recent data suggest that HRG mediates active repression of estrogen response elements via upregulation of metastasis-associated protein 1 (MTA-1), which is a component of the histone-deacetylase (HDAC) complex that is involved in repression of gene expression. Physical interactions between MTA-1, the activation factor (AF-2) domain of ERa, and HDAC 1 and 2 have been reported, implicating MTA-1 as a repressor of gene expression and a downstream effector of HRG. However, it is not clear how this transcriptional regulation occurs (Mazumdar et al., 2001) . In addition, HRG induces expression, DNA binding, and activation of the transcription factor activating transcription factor 4 (ATF-4) in processes which are dependent upon MAPK activation (Talukder et al., 2000) . To date, few studies have addressed the issue of the involvement of the HRG domains in these processes. The EGF-like domain may be involved in the proliferation of epithelial cells in response to HRG, while the other domains such as the cytoplasmic domain may be involved in other biological end points. Other studies have demonstrated that although the extracellular region of HRG is sufficient for the induction of proliferation and tumorigenesis in transgenic mice, the cytoplasmic domain is sufficient to induce apoptosis in vivo and in vitro (Krane and Leder, 1996) .
Acquired drug resistance and the resistance of tumor cells to chemotherapy have been a major obstacle in the treatment of cancer in general and of breast cancer in particular. We have shown that transfection of HRG-b2 into MCF-7 cells increases the cells' sensitivity to two drugs routinely used in breast cancer chemotherapy, Doxorubicin (Doxo) and VP-16, mediated possibly by the upregulation of topoisomerase II (Topo II) (Harris et al., 1998) . The involvement of erbB2 in the acquired drug resistance phenotype in breast cancer is controversial and the role of HRG in this process is not well understood. Recent data suggest that Topo II activity is upregulated by erbB2 phosphorylation and that the response of breast cancer cells to Doxo can be inhibited by Herceptin (Paik et al., 2000; Harris et al., 2001) . HRG can be secreted and can activate the erbB receptors, and it can also localize in the nuclei of the cells transfected with the HRG cDNA (current manuscript) or in cells treated with 125 I-HRG protein (Li et al., 1996) . To date, it is not clear which functions are attributed to the nuclear HRG and which functions, if any, are independent of erbB receptor activation.
We have shown that HRG can have a dual effect on breast cancer cells, causing the cells to become more sensitive to chemotherapy and at the same time assist the cells to become resistant to hormonal therapy and nonresponsive to hormones (Grunt et al., 1995; Harris et al., 1998) . Previous studies have also shown that the different HRG domains may be responsible, and sufficient for the variety of the HRG functions. Such studies have shown that the cytoplasmic domain of the protein is sufficient for the apoptotic effect that this protein may have, and that the EGF-like domain is sufficient for the proliferation and transformation of mammary epithelial cells (Weinstein and Leder, 2000) . We set out to investigate which structural domains of the HRG protein are sufficient for the acquired sensitivity of the cells to Doxo and furthermore, whether this characteristic can be dissociated from the transforming phenotype that is associated with the transfection of full-length HRG into the MCF-7 cells. Here we describe a structural mutant of HRG that lacks Nterminus sequences, a putative nuclear localization signal (NLS) and the cytoplasmic domain of the protein.
We have also demonstrated that this sensitization is independent of erbB or MAPK phosphorylation. Furthermore, the deletion of the two domains of HRG, leads to a change in the intracellular localization of HRG, from a defined nuclear localization in the fulllength HRG-transfected cells to a more diffused localization in the cells transfected with the deleted HRG mutant. On the other hand, this mutant is capable to confer resistance to Doxo, but it does not affect the requirements for E2 for proliferation and tumorigenesis of MCF-7 cells.
Results

MCF-7 cells transfected with the deletion mutant of HRG (HRG/M) are more sensitive to Doxo
Analysis of the HRG sequence revealed a number of structural domains (Figure 1 ). Several deletion mutants lacking different domains were constructed. This report focuses on a deletion mutant of HRG, named HRG/M, lacking the first 33 amino acids (putative NLS) and the entire cytoplasmic domain that was generated by the polymerase chain reaction (PCR) using the full-length HRG cDNA as a template. MCF-7 cells were transfected with the full-length HRG cDNA (MCF-7/HRG clones HRG1-HRG3), or with the deletion mutant of HRG (MCF-7/M clones M-M4), or with the empty vector (MCF-7/V). The cells were selected in 350 mg/ml G418 and stable clones were isolated. All clones expressed the HRG/M mutant as determined by RNAse Protection Assay (Figure 2 ). Different levels of HRG/M expression were seen, in the MCF-7/HRG/M-transfected cells. We have previously shown that HRG confers sensitivity to Doxo in MCF-7 cells, a drug used routinely in the treatment of breast cancer. Here we report our findings determining whether deletion of these domains will result in the dissociation between the diverse biological activities of HRG. Therefore, we A difference in the shape of the curve was observed in the MCF-7/M clones as compared to the MCF-7/HRG clones at the higher concentrations of Doxo. The MCF-7/M clones were slightly more resistant than MCF-7/HRG clones to the effect of Doxo, but still more sensitive than the vector control cells. However, these differences were not statistically significant. These results demonstrate that deletion of the putative NLS sequence consisting of the first 33 amino acids, in addition to the cytoplasmic domain does not affect the HRG induction of sensitization to Doxo.
Our previous studies have shown that the mechanism by which the full-length HRG increases the sensitivity of the MCF-7 cells to Doxo is related to its ability to increase Topoisomerase IIa (Topo IIa) expression, possibly via upregulation of transcription. However, the HRG/M-transfected cells did not show any modulation of Topo IIa protein (data not shown), suggesting that other, yet unknown, mechanisms are possibly involved in the HRG induction of Doxo sensitivity. This data lead us to suspect that the cytoplasmic domain, that has been previously shown to be apoptotic, is not involved in the sensitization effects of HRG, since this mutant lacks the cytoplasmic domain of the protein.
MCF-7 cells transfected with HRG-M deletion mutant maintain E2 responsiveness
HRG has previously been shown to induce the progression of MCF-7 cells to a more advanced breast cancer phenotype. We have shown that the transfection of HRG into MCF-7 cells provides the cells with the necessary stimuli to become E2 independent both in an anchorage-dependent and -independent manner in vitro and do no longer require E2 for growth in vivo. We 
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concluded that the transfection of HRG was sufficient to promote the progression of MCF-7 cells to a more aggressive phenotype, E2-independent phenotype . To determine whether the NLS and the cytoplasmic domains are involved in the acquisition of an aggressive E2-independent phenotype, we tested the ability of the MCF-7/M cells to grow in anchorage-dependent andindependent growth assays in the absence of E2. MCF-7/M, MCF-7/V, and MCF-7/HRG cells were starved from E2 in phenol red-free medium containing charcoaltreated calf serum (CCS), plated in tissue culture plates and then grown in the presence or absence of E2. Interestingly, while the MCF-7/HRG cells became E2 independent and did not require the steroid for their growth, the MCF-7/M cells responded to E2 and were sensitive to antiestrogens similarly to the MCF-7/V and the parental MCF-7 cells ( Figure 4 ). We further investigated whether the MCF-7/M grow in an anchorage-independent manner in the absence of E2. Thus, cells were cultured in E2-depleted media and assayed in a soft agar assay in the presence or absence of E2, using phenol red-free medium containing CCS. The cells were allowed to form colonies for 2 weeks and were counted using a colony counter. A striking difference was observed between the MCF-7/HRG and the MCF-7/ M cells. As expected, the MCF-7/HRG cells were virtually independent of E2 and ICI resistant in their ability to form colonies in soft agar ( Figure 5 ). In contrast, the MCF-7/M cells formed colonies only when supplemented with E2, and were sensitive to the effect of ICI ( Figure 5 ). These results show that the sequences that are present in the HRG/M construct are not sufficient for the conversion of the MCF-7 cells to E2 independence.
erbB receptors are not autophosphorylated in MCF-7/M cells, although the same mutant (as recombinant protein) induces phosphorylation of the erbB receptors in MDA-MB-453 cells Overexpression of the erbB2 receptor has been largely correlated with an aggressive phenotype in breast cancer. However, it is not clear whether all the phenotypic changes acquired by the MCF-7/HRG cells are a result of signals transmitted through activation of the erbB receptors. We have previously shown constitutive activation of the erbB receptors in MCF-7/HRG cells . Owing to the striking biological differences in the phenotype that was observed in the MCF-7/M cells as opposed to the MCF-7/HRG cells, we further investigated the phosphorylation status of the erbB receptors in the MCF-7/M cells. Cells (MCF-7, MCF-7/HRG, and MCF-7/M) were grown under serum-depleted conditions for 16 h and then the cells were assayed for erbB-tyrosine phosphorylation. Cells were then harvested, lysed and the lysates were separated on SDS-PAGE and blotted with antiphosphotyrosine antibody. Interestingly, none of the HRG/ M-transfected MCF-7 cells (MCF-7/M) demonstrated any increase in erbB-tyrosine phosphorylation when compared with the MCF-7/V cell ( Figure 6a ). In contrast, a 10-fold increase in tyrosine phosphorylation was observed in the MCF-7/HRG cells as compared to the MCF-7/V cells ( Figure 6a ). These results firmly determine that deletion of the N-terminal 33 amino acids and the cytoplasmic domain of HRG results in the inability of the mutant protein to promote autophosphorylation of the erbB receptors in an autocrine manner. This may be directly correlated to the inability
Cell Line Cell Number Figure 4 Anchorage-dependent growth in response to E2. MCF-7, MCF-7/V, MCF-7/HRG, and MCF-7/M clones were depleted of E2 for 5 days in phenol red-free IMEM with 5% CCS as described in 'Materials methods' prior to plating in 24-well plates at 10 000 cells/well. After 24 h, E2, ICI 182 780 (ICI) or ICI+E2 were added and the cells were continuously treated with the compounds, or untreated as controls. Cell growth was assessed by cell counting using the coulter counter. Results are mean of triplicate wells. Experiments were performed at least three times
Cell Line Colony Number Figure 5 Anchorage-independent growth in response to E2. Growth in soft agar assay was performed to assess the ability of the cells to form colonies in the presence or absence of E2. The cells were depleted from steroid-like compounds by growing the cells in phenol red-free IMEM containing 5% CCS. Cells were then plated in six-well plates with a soft agar in the presence or absence of E2 or treated with ICI and ICI+E2. Cells were allowed to grow and colonies were counted after 14 days; results are mean of triplicate wells. Experiments were performed at least three times Dissociation between HRG function E Atlas et al of the MCF-7/M to progress into the anchorageindependent, E2-independent phenotype. Next, we asked whether the deletion in HRG has caused an effect that would disable the protein to activate the erbB receptors and thereby cause tyrosine phosphorylation. To address this question we generated recombinant maltose-binding protein (MBP) fusion proteins containing the HRG deletion mutant HRG/ M (MBP-HRG/M) and a MBP fusion protein containing the full-length HRG (MBP-HRG). We then tested their ability to induce tyrosine phosphorylation of the erbB receptors when it is added exogenously to an erbB2-overexpressing breast cancer cell line (MDA-MB-453 cells). These cells express low levels of erbB3 and erbB4 receptor, and were chosen for convenience, since they express high levels of the erbB2 receptor. MDA-MB-453 cells were serum starved overnight, washed and then treated with MBP-HRG, MBP-HRG/M, and MBP as control. Cells were then lysed and assayed by Western blot using an antiphosphotyrosine antibody. Interestingly, the MBP-HRG/M protein induced erbB-tyrosine phosphorylation to the same extent as the full-length MBP-HRG protein. Untreated cells demonstrated low erbB-receptor phosphorylation (Figure 6b ). These results are in concordance with previously published data, which demonstrate that the EGF-like domain of HRG is sufficient to induce activation of the erbB receptors (Weinstein and Leder, 2000) . Since no autophosphorylation of the erbB receptors was observed in the MCF-7/M clones, we collected conditioned media (CM) and assessed the ability of the concentrated (100 Â ) CM to contain the biological activity able to activate the erbB receptors when exogenously added onto the erbB2-overexpressing MDA-MB-453 cells. Even under these conditions, no phosphorylation of the erbB receptor was apparent (Figure 6c ).
HRG/M protein is not secreted into the culture media of MCF-7/M cells
The results presented above demonstrate that although the deletion mutant protein activates the erbB receptors when added exogenously as a recombinant protein, it fails to do so when the HRG/M cDNA was stably transfected into MCF-7 cells (MCF-7/M). The possibility that HRG/M is trapped in the cell and cannot be secreted into the culture media and act in an autocrine manner was likely to occur. Therefore, we investigated whether the MCF-7/M clones secreted the truncated HRG/M protein into the culture media or is it sequestered in the cells. Cells (MCF-7 cells, MCF-7/V cells, MCF-7/HRG, and MCF-7/M) were grown to about 80% confluency; cells were then cultured under serum-depleted conditions for 3 days. CM from each cell lines were collected. The CM was concentrated 100 Â and assayed for the presence of the HRG/M and HRG full-length proteins by Western blot using an anti-HRG antibody (see Material and methods). The full-length HRG protein (45 kDa) was detected in the CM derived from the MCF-7/HRG cells, but no HRG/M (32 kDa) was detected in the CM derived from MCF-7/M clones, as predicted (Figure 7) . These results confirmed our hypothesis that the HRG/M protein, although stably expressed in MCF-7 cells, as seen at the mRNA and by the presence of the GFP-tagged HRG-M, is sequestered into a cellular compartment and it is not secreted into the culture media, thus preventing its autocrine action and erbB-receptor phosphorylation. It is an interesting finding that although not secreted like the full-length Figure 6 Tyrosine phosphorylation of erbB2/3 receptors in MCF-7-derived clones and MDA-MB-453 cells treated with CM or recombinant proteins. Cell lysates from MCF-7/V, MCF-7/HRG, and MCF-7/M cells were subjected to SDS-PAGE (a). The erbB2-overexpressing cell line, MDA-MB-453, was treated with recombinant HRGb1, MBP, or MBP-HRG/M prior to lysis (b), or treated with concentrated CM obtained from the MCF-7-derived clones (c). Blots were probed with an antiphosphotyrosine antibody. Cell lysates from MCF-7/V, MCF-7/HRG, and MCF-7/M cells, treated with HRGb1 or untreated as controls, were subjected to SDS-PAGE. Total erbB2 levels were assayed by blotting with an antierbB2 antibody (d). Actin levels were determined for equal protein loading (e). Experiments were performed at least three times Dissociation between HRG function E Atlas et al HRG protein, the HRG/M protein confers increased sensitivity to Doxo equally well as the full-length HRG protein demonstrating that this important function of HRG is most probably independent from activation of the erbB-signaling pathway.
MAPK is not activated in MCF-7/M clones
It has been previously shown that HRG mediates a variety of signals that have been linked to transformation, angiogenesis, and apoptosis (Krane and Leder, 1996; Grimm et al., 1998; Xiong et al., 2001) . It has been also demonstrated that HRG induces phosphorylation of MAPK and that some of the phenotypic changes dictated by HRG are dependent upon MAPK activation (Fiddes et al., 1998; Grimm et al., 1998; Lessor et al., 1998) . However, it is not clear which of the HRG domains are responsible for the different biological responses induced by HRG, and also it is unknown whether MAPK can be activated by HRG independently of erbB2 activation. Thus, we investigated whether the MCF-7/M cells exhibit changes in the level of activated MAPK. Cells (MCF-7, MCF-7/HRG, and MCF-7/M) were cultured under serum-depleted conditions for 24 h and were then lysed and subjected to SDS-PAGE. The blots were assayed using an anti-MAPK and/or antiphosphorylated MAPK. Intriguingly, the level of phosphorylated MAPK was increased only in MCF-7/HRG (Figure 8a ) cells but not in MCF-7/M cells (Figure 8b ) in basal conditions as compared to the parental or MCF-7/V cells. However, the signaling pathway is active as shown by the increase in the levels of phosphorylated MAPK when the MCF-7/M clones were treated exogenously with HRGb1. As expected, the total level of MAPK remained unchanged in all cells (Figure 8a and b) . These results suggest that the activation of MAPK is associated with the activation of the erbB receptors in the MCF-7/HRG cells. It also shows that the increased sensitivity to Doxo, which is seen in the MCF-7/M clones, is independent of the MAPK-mediated signaling and it must probably rely on other, yet unknown, intracellular interactions.
The deletion mutant HRG protein is diffused in the nucleus of the cells
We and others have demonstrated that HRG is localized mainly in the nucleus when added to SKBr-3 cells (Li et al., 1996) and unpublished data. We investigated Figure 7 Detection of full-length HRG and its mutant in cellculture media. MCF-7, MCF-7/V, MCF-7/HRG, and MCF-7/M cells were grown to subconfluency. The media were changed to serum-free medium and CM were collected and concentrated prior to electrophoresis. The presence of the HRG protein (a) or the HRG/M (b) proteins was assayed by Western blot using an anti-HRG antibody specific to the EGF-like domain. Experiments were performed at least three times Figure 8 Activation of MAPK p44/42 in MCF-7 derived clones. MCF-7/V cells and MCF-7/HRG cells were serum starved overnight. MCF-7/V, were treated with HRGb1 for 30 min at 371C or untreated. Cell lysates were separated on SDS-PAGE gels and blotted with phospho-MAPK and MAPK antibodies (a). MCF-7/M cells were serum starved overnight, treated with HRGb1 or untreated as controls, lysed and 50 mg total protein was loaded on SDS-PAGE gels. Activated MAPK was measured by Western blot with an antibody specific for the activated form of the protein. Total MAPK protein was assessed using an anti-MAPK antibody (b). Experiments were performed at least three times Dissociation between HRG function E Atlas et al whether there was a change in the cellular distribution of the mutant HRG/M protein when compared to the fulllength HRG protein. Both HRG and the HRG/M were cloned into a mammalian expression vector as fusion proteins with the green fluorescence protein (GFP) to allow their visualization. The parental MCF-7 cells were transiently transfected with the HRG-GFP or HRG/M-GFP containing constructs and the localization was analysed using confocal microscopy. The full-length HRG-GFP was observed mainly in the nucleus of the cells and furthermore, it is appeared to be tightly bound to the chromatin and concentrated in subnuclear structures (Figure 9 ), the HRG/M-GFP was still localized in the nucleus; however, it was more diffused and not tightly bound as the HRG-GFP appears. This is a very intriguing finding; at this time it is not clear whether the nuclear protein localization of the fulllength HRG is important for the sensitization to Doxo or important for any of the other phenotypic changes induced by HRG. The interactions that HRG may have in the nucleus and its function to sensitize cell to Doxo are sill unknown and are under current investigation in our laboratory.
Discussion
HRG is a growth factor that is involved in tumorigenicity and tumor progression (Li et al., 1996; Lupu et al., 1996; Hijazi et al., 2000; Tsai et al., 2000) . Here we demonstrate several biological effects rendered by a deletion mutant of HRG that lack a putative NLS and the cytoplasmic domain as compared with the fulllength HRG. Our studies have shown that transfection of a deletion mutant of HRG/M rendered MCF-7 cells increased sensitivity to the treatment with Doxo. The results clearly demonstrate that these HRG sequences are sufficient for the sensitization of MCF-7 cells to the effect of the chemotherapeutic drug Doxo. We have previously shown that transfection of HRG-cDNA into MCF-7 cells increases the cells sensitivity Doxo. This increase in sensitivity was correlated with an increase in the expression of Topo II at the mRNA and the protein level (Harris et al., 1998) . However, the increased sensitivity mediated by the mutant HRG/M did not promote an increase in Topo II expression. The results reported here support a different mechanism for the sensitization of the MCF-7 cells to Doxo mediated by HRG or HRG/M, which appears to involve different HRG domains. It is possible that although an upregulation of Topo II has not been observed, post-translational modifications of the protein may be responsible for the increased sensitivity. Such modifications have been previously reported in the literature to be involved in the cells susceptibility to Doxo in other systems (Li et al., 1996; Aoyama et al., 1998; Matsumoto et al., 1999) . However, it is also possible that the increased sensitivity to the chemotherapeutic agent is because of the synergistic effect of the drug and the truncated HRG protein via upregulation of proteins involved in cell cycle arrest and apoptosis, which implies that the mechanisms by which this HRG mutant increases the cells sensitivity to Doxo are is fundamentally different than that previously thought. Preliminary studies in the laboratory suggest that changes in p21
Waf-1 levels and localization may be partially involved in the sensitization to Doxo. Since the localization of the mutant is mainly nuclear and certainly intracellular, these differences must be modulated via interactions with nuclear proteins and possibly with transcriptional regulators. These mechanisms are currently under investigation in our laboratory.
Our studies have shown that the introduction of HRG cDNA into MCF-7 cells provides the cells with a growth advantage in E2-depleted medium, as well as the ability to form tumors in vivo in the absence of E2 stimulation . It has also been shown that the extracellular domain of HRG containing the EGF-like domain is sufficient for the tumorigenic effect, while the intracellular domain is sufficient for the apoptotic effect that HRG can have in some systems Weinstein and Leder, 2000) . However, these studies were conducted in transgenic mice, under steroid stimulation.
We investigated whether HRG/M that retains the sensitization function of the full-length HRG also promotes a more aggressive phenotype similarly to the full-length HRG protein. Fascinatingly, we were able to Figure 9 Localization of the GFP-HRG and GFP-HRG/M proteins in MCF-7 cells. MCF-7 cells were plated in Lab-Teck chambers and transiently transfected with constructs containing GFP-HRG or GFP-HRG/M sequences as described in 'Materials and methods'. Intracellular localization of the GFP control, GFP-HRG, and GFP-HRG/M proteins was visualized using confocal microscopy Dissociation between HRG function E Atlas et al dissociate between the aggressive phenotype associated with HRG overexpression and its induction of sensitization to Doxo. Our results reveal that deletion of the NLS and the cytoplasmic domains of HRG inhibited the ability to promote cell growth and proliferation of MCF-7 cells in anchorage-dependent and -independent growth. Moreover, this deletion prevented the ability of HRG to promote cells to become E2 independent and antiestrogen resistant. These results support our hypothesis that the intracellular HRG and furthermore, the different structural domains of HRG contribute to the distinct functions of HRG. Furthermore, these data are in concordance with our initial hypothesis that the sensitization to chemotherapy can be dissociated from the other functional aspects of the HRG and that not all of the HRG-mediated effects are via the binding of the protein to the erbB receptors. The notion that the HRG structural domains contribute to different actions are supported by the results obtained with the Neuregulins in the nervous system. Mutation of the intracellular domain of Neuregulin results in embryonic defects similar to these that are seen in animals in which the entire gene was deleted (Liu et al., 1998) . Furthermore, deletion of the cytoplasmic tail of Neuregulin b1 type I, but not of the type III b1 reduced its secretion into the media in PC12 cells, and affected its localization ). However, very few studies investigated the functions of the HRG cytoplasmic or extracellular domains. Our study concludes that neither the cytoplasmic tail of the HRG nor its putative NLS domain is needed for the sensitization of the cells to Doxo, but are possibly required for the acquisition of anchorage and E2 independence, and antiestrogen resistance. Since this HRG/M contains the EGF-like domain, which has been associated with most biological activities of HRG mediated via the erbB receptors, we investigated the phosphorylation status of the erbB receptors in the MCF-7/M cells. The results presented in Figure 6a clearly show that there was no increase in the phosphorylation status of the erbB receptors in the MCF-7/M cells in basal conditions, although it was clear that the recombinant HRG/M protein is biologically active, since it phosphorylated the erbB receptors when it was added exogenously to the erbB2-overexpressing cell line MDA-MB-453 cells (Figure 6b ).
These somewhat puzzling results lead us to examine the ability of the HRG/M to be secreted into the cultured media of the cells and act in an autocrine manner. It has been previously reported that the transmembrane (TM) domain of the protein has an important role for the secretion of the protein and its prior localization into the membrane as a TM protein . However, it was also reported that the HRG g-isoform that does not contain the TM or the cytoplasmic tail of the protein could be secreted using the hydrophobic N-terminal sequence (Schaefer et al., 1997) . Since the HRG/M used in our studies did not contain the TM domain or a hydrophobic N-terminal sequence it should not be secreted into the cultured media. Our results support these previous findings, since while the MCF-7/HRG cells secreted HRG into the media, MCF-7/M cells did not secrete the mutated HRG protein (Figure 7a ).
ErbB2 has been associated with the failure to endocrine therapy, which also correlates with E2 independence. We have shown that the expression and autocrine function of HRG are sufficient to confer E2 independence in vivo and in vitro . Other studies have concluded that the lack of E2 response mediated by HRG occurs through the repression of E2 response via active transcriptional repression mediated by members of the HDACs (Mazumdar et al., 2001) . However, it is not clear whether this effect mediated by HRG in the E2-dependent cell line MCF-7 requires the activation of erbB2 or is it an event, which is independent of the phosphorylation of the receptor. Furthermore, it is not clear whether only some of the structural domains of HRG are necessary for this effect. In this study, we show that the HRG sequences used did reduce somewhat the responsiveness of the cells to E2, but did not allow the MCF-7 cells to bypass their E2 requirements and become E2 independent. It is not clear, however, whether this result is because of the lack of erbB phosphorylation or the lack of a necessary HRG sequence, which may be responsible for the lack of E2 response via other yet unknown mechanisms.
Data from the literature suggest that HRG utilizes the MAPK p42 pathway to transactivate a number of target genes, such as ATF-4 but can also activate the PI-3 kinase pathway, and the AKT-mediated signaling (Liu et al., 1999) . We investigated whether activation of MAPK occurs in the absence of the erbB2 autophosphorylation. As expected, overexpression of the mutant HRG did not activate MAPK (Figure 8b ) and suggests that the phosphorylation of this downstream effector of HRG is dependent on the activation of the erbB receptor and the secretion of HRG into the cultured media. Other downstream effectors such as JNK, p38MAPK could also be implicated in the sensitization of the cells to Doxo and the status of these proteins will be investigated in the future. However, studies in the laboratory implicate the apoptotic process in the sensitization of the mutant protein to Doxo.
Our previous studies clearly demonstrate that HRG is not only secreted into the culture media of but it is also localized in the nucleus of SKBr-3 cells (data not shown). We now demonstrate that a similar localization is observed when MCF-7 cells were transfected with a GFP-HRG fusion protein. When HRG/M-GFP cDNA was transfected into the cells, the HRG/M protein was still localized mainly in the nucleus (Figure 9 ), and although still nuclear it appears more diffused. These results demonstrate that the sequences deleted in the HRG/M protein are important for the localization of the HRG protein in the subnuclear structures. At this point in time we do not know what these nuclear structures are or what interactions are driving the protein into these structures. These results show that what was identified by us as NLS does not truly function as a nuclear localization signal. It is possible that there are several other consensus sequences that have homology to nuclear localization signals in the mutant protein.
In fact, another group has shown that there are few other putative NLS sequences in the immunoglobulin and in the EGF-like domains, and deletion of these sequences affects the nuclear localization of the Nterminal portion of HRGg (personal communication). The nature of the interactions of HRG and its domains with the nucleus is currently investigated in our laboratory.
In summary, the results presented here clearly demonstrate that the first 33 amino acids and the cytoplasmic domains of HRG, which are lacking in the HRG/M protein, are necessary for the ability of HRG to act in an autocrine manner and promote anchorageindependent growth of MCF-7 cells. Furthermore, the aggressive phenotype of MCF-7 cells that has been correlated with the transfection of HRG cannot be associated with the transfection of the HRG/M deletion mutant into the cells. However, the sensitization function of HRG to Doxo remains intact, and therefore can be dissociated from the protein's function as a promoter of breast cancer progression. We clearly demonstrated that the sensitization of the cells to Doxo was independent of the activation of the erbB receptor activation. These results support the hypothesis that the HRG protein acts independently of the erbB receptor expression and activation and it is involved on its own in other cellular interactions.
Materials and methods
DNA constructs and generation of recombinant proteins
The deletion mutant of HRGb2 was generated by PCR using the HRGb2 cDNA accession number 183996 as a template and the primers 5 0 -GGAAGCTTTTGAAAGAGATGA-AAAGC-3 0 and 5 0 -GGTCTAGAGCCG GTTAATGGTCAG-CAC-3 0 corresponding to a fragment of 621 bp from nucleotide 574 to nucleotide 1195 of the sequence. The PCR product was cloned into the mammalian expression vector pRC-CMV using the HindIII and XbaI sites and transfected into the MCF-7 cell line after sequencing.
For the generation of recombinant proteins, the deletion mutant PCR fragment or full-length cDNA was amplified using the primers: 5 0 -GGGAATTCTTGAAAGAGATGAA-AAGC-3 0 and 5 0 -GGAAGCTTTCAGCCGGTTATGGTCA-GCAC-3 0 , and 5 0 -GGGAATTCATGTCCGAGCG-CAAAG-3 0 and 5 0 -GGAAGCTTTCATTCTGTTGGATACTGATA-3 0 , respectively. The PCR fragments were cloned into the MBP fusion expression vector pMAL-c2 (New England BioLabs Inc.) linearized with EcoRI and HindIII. Recombinant proteins were generated as per the manufacturer's instructions. For the generation of GFP fusion HRG or HRG/M, DNA fragments were released from the pRC-CMV vector, using the enzymes HindIII and XbaI filled in with Klenow redigested with HindIII and cloned into the pEGFP-N2 vector cut with HindIII and SmaI.
Cell culture and transfection
MCF-7 cells were purchased from the American Type Culture Collection (ATCC) and routinely cultured in phenol redcontaining IMEM (Biofluids), supplemented with 5% (v/v) fetal bovine serum (FBS) and 2 mm l-glutamine, at 371C in a humidified atmosphere with 5% CO 2 .
Generation of stable clones was accomplished as follows: MCF-7 cells were plated in 100 mm plates 24 h prior transfection. Cells were then transfected with HRGb2 cDNA (Liu et al., 1999) , with the deletion mutant of HRG containing construct (HRG/M) in pRC-CMV, or with the mammalian expression vector pRC-CMV as control, using FuGENE as per the manufacturer's instructions (Roche). Briefly, 3.3 mg DNA was mixed with 33 ml of the FuGENE reagent in a total volume of 330 ml serum-free media. After 15 min incubation, the DNA/FuGENE mix was added onto the cells. At 48 h post-transfection, the cells were selected in 350 mg/ml G418 and stable clones were selected and expanded.
RNAse protection assay
The antisense riboprobe plasmids for HRG and GAPDH were constructed as described previously (Liu et al., 1999) . In brief, radioactive riboprobe was prepared by in vitro reverse transcription of the linearized DNA template, using a bacterial phage RNA polymerase in the presence of [ 32 P]UTP. Total RNA was extracted by Tripure isolation solution (Roche). RNA (20 mg) was hybridized with 100 000 c.p.m. of 32 P-labeled HRG riboprobe for 16 h at 501C.
32 P-labeled GAPDH riboprobe (10 000 c.p.m.) was added to each sample as an internal control. Hybridized RNA samples were digested with RNase A for 30 min at 281C. The reaction was terminated by incubating with proteinase K (250 mg/ml) and 0.5% SDS for 15 min at 371C. After phenol extraction, RNA samples were co-precipitated with 10 mg of yeast tRNA in absolute ethanol. RNA was redissolved in a denaturing loading buffer and resolved by electrophoresis on a 6% polyacrylamide-urea gel. Protected fragments were visualized by autoradiography. [ 32 P]dCTP end-labeled pBR322/MspI (New England Biolabs) was used as a molecular weight marker.
Cytotoxicity assay
MCF-7, MCF-7/V, MCF-7/HRG (clones 1 and 2) and MCF-7/M (clones 1-3) were plated at 1000 cells/well in 96-well plates, in IMEM 5% FBS. After 24 h, the cells were treated with the indicated concentrations of Doxo or untreated as controls. Viability was assessed on the 7th day using a Cell Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega).
Anchorage-dependent growth assays
Cells were cultured in serum containing IMEM media. When cells reached 60-70% confluent, the media were replaced with phenol red-free IMEM supplemented with 5% charcoal-stripped FBS for 4 days, with at least three changes to ensure complete depletion of estrogen-like components from the media. Cells (10 000/well) were then plated in triplicate in 24-well plates and treated with E2 (1 nm), ICI 182 780 (ICI) (100 nm), ICI+E2 or untreated as controls. Cell number was determined using a Coulter counter at days 0, 3, and 5.
Anchorage-independent growth assays MCF-7-derived cells were cultured in phenol red-free IMEM with 5% charcoal-stripped FBS for 4 days, with at least three changes. Cells (20 000/well) were resuspended in 0.35% agar containing E2, ICI, ICI+E2 or not, and plated in triplicate onto a 0.6% bottom agar layer in six-well plates. Colonies were counted after 14-16 days when they reached a size of 100 mm in diameter, using the Accu-count 2000 colony counter (Biologic).
Western blot analysis
MCF-7/HRG cells (clones HRG1 or HRG2), MCF-7/V cells, and MCF-7 HRG/M (clones M1-3) (5 Â 10 5 ) were plated in IMEM containing 5% FBS, in six-well plates. After 24 h, cells were washed three times with serum-free media, and serum starved overnight. MCF-7/V and MCF-7/M cells (5 Â 10 5 ) were treated with HRGb1 (Neomarkers, CA, USA) (30 ng/ml) for 30 min at 371C, under serum-free conditions or left untreated. All cells were lysed with lysis buffer, consisting of 50 mm HEPES 1% Triton X-100, 0.15 m NaCl, 10% glycerol, 2 mm EDTA, and 50 mm ZnCl 2 , protein quantification was performed using the BCA reagent (Pierce, IL, USA), and 50 mg of total protein was loaded onto a 12% SDS-PAGE. For the assessment of the secreted HRG or HRG/M in conditioned media, 70-80% confluent MCF-7/HRG cells (clones HRG1 and HRG2), MCF-7/V cells, and MCF-7 HRG/M (clones M1-3) were cultured in serum-free media for 24 h and changed to serum-free media for another 48 h. The CM were collected and concentrated 100 Â in centricon columns (Millipore). The proteins were transferred onto nitrocellulose membranes and blotted with anti-MAPK, antiphospho-MAPK antibodies (Cell Signaling Technology, MA, USA), antiphosphotyrosine 4G10 clone (Upstate Biotechnology, NY, USA), anti-erbB2 (Oncogene), antiactin (Santa Cruz Biotecnology), and anti-HRG Ab-1 (Neomarkers, CA, USA). The membranes were developed using ECL reagents (Amersham Pharmacia Biotech, NJ, USA) and autoradiography.
Phosphorylation assays
Confluent MCF-7/HRG cells (70-80%) (clones HRG1 and HRG2), MCF-7/V cells, and MCF-7 HRG/M (clones M1-3) were cultured in serum-free media for 24 h and changed to serum-free media for another 48 h. The CM were collected and concentrated centricon (Millipore). Protein concentrations were normalized according to cell number. The concentrated CM were applied onto MDA-MB-453 cells, an erbB2 overexpressing cell line that have been plated at 5 Â 10 5 cells/well in a six-well plate, and serum starved overnight. The cells were lysed in the lysis buffer, consisting of 50 mm HEPES 1% Triton X-100, 0.15 m NaCl, 10% glycerol, 2 mm EDTA, and 50 mm ZnCl 2 , protein quantification was performed using the BCA reagent (Pierce, IL, USA), and 50 mg of total protein was loaded onto a 3-8% gradient Tris-acetate gels.
Cellular localization
MCF-7 cells were plated into Lab-Teck chambers (Falcon) and transiently transfected with constructs (1 mg DNA) containing GFP-HRG and GFP-HRG/M or the pEGFP-N2 vector (Clontech) using FuGENE transfection reagent (Roche). At 48 h post-transfection, the cells were washed with PBS, fixed in 4% paraphormaldehyde, and the slides were mounted with Crystal mount media. The localization of the GFP proteins was visualized by confocal microscopy. 
